Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck

Cancer

Volumn 116, Issue 10, 2010, Pages 2350-2359

  Li, Fanglin ^a,b   Sturgis, Erich M ^a   Chen, Xingming ^a,c   Zafereo, Mark E ^a   Wei, Qingyi ^a   Li, Guojun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHANDONG UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Genetic susceptibility; Head and neck cancer; Molecular epidemiology; p53 polymorphism; Second primary malignancy; Squamous cell carcinoma; Survival

Indexed keywords

PROTEIN P53;

ADULT; AGED; ALCOHOL CONSUMPTION; AMINO ACID SUBSTITUTION; ARTICLE; CODON; ETHNICITY; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SECOND CANCER; SMOKING; SQUAMOUS CELL CARCINOMA; ADOLESCENT; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; RISK; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CODON; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, GENETIC; RISK;

EID: 77952562141     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25072     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184-194.
3. American Cancer Society, Inc. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
4. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys. 1989;17:449-456.
5. Kotwall C, Razack MS, Sako K, Rao U. Multiple primary cancers in squamous cell cancer of the head and neck. J Surg Oncol. 1989;40:97-99. (Pubitemid 19068418)
6. Cohn AM, Peppard SB. Multiple primary malignant tumors of the head and neck. Am J Otolaryngol. 1980;1:411-417.
7. Day GL, Blot WJ. Second primary tumors in patients with oral cancer. Cancer. 1992;70:14-19.
8. Yamamoto E, Shibuya H, Yoshimura R, Miura M. Site specific dependency of second primary cancer in early stage head and neck squamous cell carcinoma. Cancer. 2002;94:2007-2014. (Pubitemid 34270054)
9. Vikram B, Strong EW, Shah JP, Spiro R. Second malignant neoplasms in patients successfully treated with multimodality treatment for advanced head and neck cancer. Head Neck Surg. 1984;6:734-737. (Pubitemid 14185491)
10. Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst. 1994;86:131-137.
11. Do KA, Johnson MM, Lee JJ, et al. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004;101:2837-2842.
12. Ng AK, Travis LB. Second primary cancers: an overview. Hematol Oncol Clin North Am. 2008;22:271-289.
13. Gilbert ES, Stovall M, Gospodarowicz M, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res. 2003;159:161-173.
14. Foulkes WD, Brunet JS, Sieh W, et al. Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ. 1996;313:716-721. (Pubitemid 26313071)
15. Lukas J, Lukas C, Bartek J. Mammalian cell cycle check-points: signalling pathways and their organization in space and time. DNA Repair. 2004;3:997-1007. (Pubitemid 38997942)
16. Helton ES, Chen X. p53 modulation of the DNA damage response. J Cell Biochem. 2007;100:883-896.
17. Brachman DG, Graves D, Vokes E, et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res. 1992;52:4832-4836.
18. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat. 2003;21:182-191. (Pubitemid 36292961)
19. Gallo O, Bianchi S. p53 expression: a potential biomarker for risk of multiple primary malignancies in the upper aero-digestive tract. Eur J Cancer B Oral Oncol. 1995;31B:53-57.
20. Homann N, Nees M, Conradt C, et al. Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma. Clin Cancer Res. 2001;7:290-296. (Pubitemid 32183032)
21. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357-365.
22. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809-819.
23. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092-1100. (Pubitemid 29046852)
24. Han J, Cox DG, Colditz GA, Hunter DJ. The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol Carcinog. 2006;45:694-700. (Pubitemid 44406640)
25. Yi SY, Lee WJ. A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol. 2006;12:6536-6539. (Pubitemid 44742591)
26. Ezzikouri S, El Feydi AE, Chafik A, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res. 2007;37:748-754.
27. An J, Liu Z, Hu Z, et al. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 2007;16:1633-1638.
28. Zhensheng L, Calderon JI, Zhang Z, et al. Polymorphisms of vitamin D receptor gene protect against risk of head and neck cancer. Pharmacogenet Genomics. 2005;15:159-165.
29. Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer. 1932;51:1358.
30. Bergamaschi D, Samuels Y, Sullivan A, et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet. 2006;38:1133-1141.
31. Chen K, Hu Z, Wang LE, et al. Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:4300-4305. (Pubitemid 47105994)
32. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2002;183:123-130. (Pubitemid 34628415)
33. Hamel N, Black MJ, Ghadirian P, Foulkes WD. No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer. 2000;82:757-759. (Pubitemid 30085220)
34. Scheckenbach K, Lieven O, Gotte K, et al. p53 codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev. 2004;13:1805-1809.
35. Lu J, Wang LE, Xiong P, et al. 172G>T variant in the 50 untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant. Carcinogenesis. 2007;28:988-994.
36. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108:196-199.
37. Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25:3489-3500.
38. Do KA, Johnson MM, Doherty DA, et al. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control. 2003;14:131-138.
39. Hashibe M, Ritz B, Le AD, et al. Radiotherapy for oral cancer as a risk factor for second primary cancers. Cancer Lett. 2005;220:185-195.
40. Ko Y, Abel J, Harth V, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res. 2001;61:4398-4404.
41. Argiris A, Brockstein BE, Haraf DJ, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004;10:1956-1962.
42. Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM. DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope. 2005;115:2221-2231.
43. Minard CG, Spitz MR, Wu X, Hong WK, Etzel CJ. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer. 2006;106:2636-2644.
44. Benjamin Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B. 1995;57:289-300.